Open AccessSynergistic Cooperation Between Sunitinib and Cisplatin Promotes Apoptotic Cell Death in Human Medullary Thyroid Cancer
Author(s) -
Alessia Lopergolo,
Valentiicolini,
Enrica Favini,
Laura Dal Bo,
Monica Tortoreto,
Denis Cominetti,
Marco Folini,
Paola Perego,
Vittoria Castiglioni,
Eugenio Scanziani,
Maria Grazia Borrello,
Nadia Zaffaroni,
Giuliana Cassinelli,
Cinzia Lanzi
Publication year - 2013
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2013-2574
Subject(s) - sunitinib , cisplatin , cancer research , apoptosis , programmed cell death , medullary thyroid cancer , medicine , tyrosine kinase , tyrosine kinase inhibitor , pharmacology , autophagy , cancer , endocrinology , thyroid cancer , chemistry , receptor , chemotherapy , biochemistry
Tyrosine kinase inhibitors represent a new treatment option for patients with advanced medullary thyroid cancer (MTC). However, cures have not been achieved with current available agents used in monotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom